Biotechnology company Hummingbird Bioscience has begun two Phase Ib clinical trials of HMBD-001 in Australia.
The trials are enrolling squamous non-small cell lung carcinoma (sqNSCLC) patients and those with genetic aberrations in HER3 signalling.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,